Literature DB >> 17460812

Effect of parathyroidectomy on quality of life and neuropsychological symptoms in primary hyperparathyroidism.

Theresia Weber1, Monika Keller, Isabella Hense, Alexander Pietsch, Ulf Hinz, Tobias Schilling, Peter Nawroth, Ernst Klar, Markus W Büchler.   

Abstract

Neuropsychological symptoms are found in a certain number of patients with primary hyperparathyroidism (PHPT). Preoperative and postoperative quality of life, anxiety, and depression are measured to analyze the impact of parathyroidectomy on these symptoms. In this prospective study, 66 patients underwent parathyroidectomy for PHPT and were evaluated pre- and postoperatively with two validated psychometric instruments (HADS, PHQ-9). Health-related quality of life was measured with a 12-item short-form health survey (SF-12). Preoperatively, the median physical component score (SF-12) of 43.0 and mental component score of 43.5 were lower than those of the general population (52.8 and 54.2 points, respectively). One year postoperatively the mental component score increased to 48.6 (p = 0.011), whereas the physical functioning scale scored 45.3 and therefore did not change significantly (p = 0.585). Preoperatively, symptoms of depression were found in 23.4% of the patients, and 15.6% of the patients displayed symptoms of anxiety (HADS). The prevalence of depression was significantly higher in patients with preoperative serum calcium levels > 11.2 mg/dl (2.8 mmol/L) (p = 0.015). Twelve months postoperatively, the overall proportion of patients with anxiety and depression decreased to 7.8% and 15.7%, respectively (p = NS). The severity of depression as measured with the PHQ-9 declined postoperatively as well. In this study, preoperative neuropsychological symptoms were related to the serum calcium levels. Postoperative health-related quality of life improved significantly. Among patients with preoperative symptoms of depression and anxiety, both symptoms were alleviated significantly at the 12-month follow-up. Therefore, surgery for PHPT seems to be effective in reducing neuropsychological morbidity associated with PHPT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17460812     DOI: 10.1007/s00268-007-9006-6

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.282


  29 in total

1.  Six hundred fifty-six consecutive explorations for primary hyperparathyroidism.

Authors:  Robert Udelsman
Journal:  Ann Surg       Date:  2002-05       Impact factor: 12.969

2.  Prospective surgical outcome study of relief of symptoms following surgery in patients with primary hyperparathyroidism.

Authors:  J L Pasieka; L L Parsons
Journal:  World J Surg       Date:  1998-06       Impact factor: 3.352

Review 3.  International experiences with the Hospital Anxiety and Depression Scale--a review of validation data and clinical results.

Authors:  C Herrmann
Journal:  J Psychosom Res       Date:  1997-01       Impact factor: 3.006

4.  Unilateral versus bilateral neck exploration for primary hyperparathyroidism: a prospective randomized controlled trial.

Authors:  Anders Bergenfelz; Pia Lindblom; Sten Tibblin; Johan Westerdahl
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

5.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

6.  Maintained normalization of cardiovascular dysfunction 5 years after parathyroidectomy in primary hyperparathyroidism.

Authors:  Inga-Lena Nilsson; Jan Aberg; Jonas Rastad; Lars Lind
Journal:  Surgery       Date:  2005-06       Impact factor: 3.982

7.  Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease.

Authors:  Robert A Wermers; Sundeep Khosla; Elizabeth J Atkinson; Sara J Achenbach; Ann L Oberg; Clive S Grant; L Joseph Melton
Journal:  J Bone Miner Res       Date:  2005-09-19       Impact factor: 6.741

8.  Patient-based surgical outcome tool demonstrating alleviation of symptoms following parathyroidectomy in patients with primary hyperparathyroidism.

Authors:  Janice L Pasieka; Louise L Parsons; Michael J Demeure; Stuart Wilson; Peter Malycha; Jean Jones; Beth Krzywda
Journal:  World J Surg       Date:  2002-05-21       Impact factor: 3.352

9.  Primary hyperparathyroidism surgical management since the introduction of minimally invasive parathyroidectomy: Mayo Clinic experience.

Authors:  Clive S Grant; Geoffrey Thompson; David Farley; Jon van Heerden
Journal:  Arch Surg       Date:  2005-05

10.  The hospital anxiety and depression scale.

Authors:  A S Zigmond; R P Snaith
Journal:  Acta Psychiatr Scand       Date:  1983-06       Impact factor: 6.392

View more
  15 in total

1.  Persistent symptomatic improvement in the majority of patients undergoing parathyroidectomy for primary hyperparathyroidism.

Authors:  Preethi Gopinath; Gregory P Sadler; Radu Mihai
Journal:  Langenbecks Arch Surg       Date:  2010-07-25       Impact factor: 3.445

2.  Hyperparathyroidism, an emerging disease.

Authors:  Guido Gasparri; Nicola Palestini; Silvia Catalano; Francesca Talarico; Clemente Ronchetta; Gregorio Balbo; Michele Camandona
Journal:  Updates Surg       Date:  2010-11-13

3.  Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery.

Authors:  Aliya Khan; John Bilezikian; Henry Bone; Andrey Gurevich; Peter Lakatos; Waldemar Misiorowski; Liudmila Rozhinskaya; Marie-Louise Trotman; Miklós Tóth
Journal:  Eur J Endocrinol       Date:  2015-01-30       Impact factor: 6.664

4.  Neurocognitive dysfunction: a predictor of parathyroid hyperplasia.

Authors:  Daniel Repplinger; Sarah Schaefer; Herbert Chen; Rebecca S Sippel
Journal:  Surgery       Date:  2009-12       Impact factor: 3.982

5.  Timing of symptom improvement after parathyroidectomy for primary hyperparathyroidism.

Authors:  Sara E Murray; Priya R Pathak; David S Pontes; David F Schneider; Sarah C Schaefer; Herbert Chen; Rebecca S Sippel
Journal:  Surgery       Date:  2013-10-04       Impact factor: 3.982

6.  Clinical presentation and management of patients with primary hyperparathyroidism of the Swiss Primary Hyperparathyroidism Cohort: a focus on neuro-behavioral and cognitive symptoms.

Authors:  A Trombetti; E R Christ; C Henzen; G Gold; M Brändle; F R Herrmann; C Torriani; F Triponez; M Kraenzlin; R Rizzoli; C Meier
Journal:  J Endocrinol Invest       Date:  2016-01-07       Impact factor: 4.256

7.  Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism.

Authors:  Claudio Marcocci; Philippe Chanson; Dolores Shoback; John Bilezikian; Laureano Fernandez-Cruz; Jacques Orgiazzi; Christoph Henzen; Sunfa Cheng; Lulu Ren Sterling; John Lu; Munro Peacock
Journal:  J Clin Endocrinol Metab       Date:  2009-05-26       Impact factor: 5.958

8.  Pasieka's parathyroid symptoms scores correlate with SF-36 scores in patients undergoing surgery for primary hyperparathyroidism.

Authors:  Radu Mihai; Gregory P Sadler
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

9.  Clinical characteristics and depression score response after parathyroidectomy in primary hyperparathyroidism.

Authors:  Ann E Kearns; Rachel P Espiritu; Kristin Vickers Douglass; Prabin Thapa; Robert A Wermers
Journal:  Clin Endocrinol (Oxf)       Date:  2019-06-25       Impact factor: 3.523

10.  Neuropsychological features in primary hyperparathyroidism: a prospective study.

Authors:  Marcella D Walker; Donald J McMahon; William B Inabnet; Ronald M Lazar; Ijeoma Brown; Susan Vardy; Felicia Cosman; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2009-03-31       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.